logo
'Horrific' Photo Made This Dad Lose Half His Weight in a Year without Medication. He's Since Dropped 220 Lbs.

'Horrific' Photo Made This Dad Lose Half His Weight in a Year without Medication. He's Since Dropped 220 Lbs.

Yahoo21 hours ago
NEED TO KNOW
A U.K. dad of two was inspired to change his diet and start exercising after he saw his wedding photos, saying he looked 'horrific' in the images
Dale Forrest, 38, first limited his calories before walking 10,000 steps a day — and within three months, had lost nearly 100 lbs.
He said he didn't turn to GLP-1 medication to lose weight because he wanted to see what could be done 'naturally'A father of two lost more than 220 lbs. — without using medication — after his 'horrific' wedding photo inspired him to change his diet and begin exercising.
For Dale Forrest, 36, weight has always been a struggle. Ten years ago, he lost nearly 200 lbs. by giving up alcohol and watching what he ate, according to the Daily Mail.
However, the weight piled back on, he said, as he struggled with declining mental health and self-confidence.
'I was living alone in a studio apartment. All my mates had girlfriends, wives and kids and I was just lonely,' Forrest, who hails from the English town of Bolton, said. 'I also didn't like my job at the time. As soon as I put a little weight back on, everything just spiraled.'
His mental health improved after met his now-wife, Kat, in 2021, and they welcomed two sons, Bailey, 3, and Tate, 1.
But the weight stayed on — until September 2024, when Forrest saw the pictures from his wedding.
https://people-app.onelink.me/HNIa/kz7l4cuf
'I thought I looked horrific,' Forrest said, per the Daily Mail. 'The first thing I said to my wife was, 'I need to make a change.' '
At the time, Forrest started his day with three pasties — a savory meat-filled turnover — and ended it with pizza and beer. But after seeing the photos, Forrest said he threw away all the snacks in the house 'so they weren't there to tempt me,' and limited his caloric intake.
The goal, he said, was to lose enough weight to begin exercising.
'I was so unhealthy to the extent that I couldn't walk 100 meters [0.06 miles] before feeling tired,' he said. 'I knew I wouldn't be able to exercise until I had lost some initial weight.'
A month later, he'd lost nearly 30 lbs., and began walking, aiming for 10,000 steps a day. By December 2024 — three months after he first saw the wedding photos — he'd lost nearly 100 lbs., and began hitting the gym, something he described as 'terrifying.'
'I thought everyone was looking at me thinking, 'Why is this guy here?' ' he shared. 'I was self-conscious of my body, but especially my legs.'
Nearly a year after he started his fitness journey, Forrest is training for a charity boxing match, and now weighs about 210 lbs. — half of what he weighed in September 2024.
Although he said he 'did this the hard way,' he explained that he didn't pursue a GLP-1 medication because "I wanted to see what I could do naturally and what was possible.'
He now shares his continued fitness journey on TikTok, where he said in one video that his sons are "my reason for living, getting healthier, and improving my quality of life."
Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
'Good old fashioned exercise and diet got me here,' he said, per the Daily Mail. And here, Forrest said, is a place where he 'can now play with my children. Before I [lost the weight], I used to tell them to play with their mom.'
He added, 'It's nice when they ask, 'Daddy, can you put me on your shoulders?' and I can be there for them. It's the best decision I have ever made."
Read the original article on People
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Yahoo

time7 minutes ago

  • Yahoo

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Yahoo

time24 minutes ago

  • Yahoo

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust

Yahoo

time32 minutes ago

  • Yahoo

Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust

More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store